Bispecific antibodies (bsAbs) bind the specificities of two antibodies and combine them to simultaneously recognize different antigens or epitopes. Because of that interest in their use for therapeutic applications has increased considerably. With the development of bsAb technology platform, the combination selection of targets is becoming the key point of competition. Among the bsAb programs under development currently, the combination of CD3 and tumor surface targets are the most popular targets pairs. And the new targets of Immune cell will also lead to more choice in targets combination in the future.

Hot targets for bispecific antibodies

CD3 proteins        PD-1/PD-L1 proteins       CD47 proteins        Full lenght CD20 Proteins

With nearly 30 years of experience producing functional antibodies for immune-focused research, Bio X Cell applies the same established manufacturing processes to every bispecific reagent. Production teams understand the parameters that influence study outcomes, from scalable expression to defined purification and QC processes.

This expertise allows researchers to request catalog or custom bispecifics with confidence, knowing each reagent is built for reproducibility and biological integrity.

Bio X Cell supports bispecific research through ready-to-use formats and fully customizable engineering services.

For specialized applications that require alternative formats or non-catalog targets, Bio X Cell provides:

Flexible format selection

Custom antigen pairing

Species-matched designs

Fc silencing or isotype switching

Recombinant expression and purification at research scale

                                 All Bio X Cell bispecific antibodies are produced to support reproducible performance                                                      in demanding preclinical systems. Each reagent is:

≥ 95 percent pure

≤ 0.5 EU per mg endotoxin

Carrier-free and preservative-free

Screened for murine pathogens

Supported by consistent lot-to-lot performance

These specifications support dependable performance across in vivo studies and advanced in vitro systems, including organoid and organ-on-chip models. This consistency helps researchers connect mechanistic insights from controlled in vitro assays to physiologically relevant outcomes in living systems.

BsAb Engineering

Over the past decades, the three antibody generation strategies, chemical conjugation, hybrid hybridomas and genetic engineering have resulted in over 67-70 different formats of bispecific antibodies. These BsAbs have been widely researched in diagnostic and therapeutic fields. Creative Biolabs can provide BsAb engineering service to adjust the properties of BsAbs such as valency, size, half-life, flexibility, etc., to meet specific requirements.

BsAb Analysis

Bispecific antibodies have reached marvellous clinical results. To develop BsAbs for treating diseases, it is critically important to perform comprehensive analysis for BsAbs to guarantee their quality and function. Quality assessment, characteristic analysis, as well as preclinical research are necessary during the different stages of BsAb development.

BsAb Manufacturing

With the rapid development of recombinant protein technology, numerous BsAbs have emerged as therapeutic proteins. Creative Biolabs offers three approaches to develop BsAbs for customers: hybrid-hybridoma technology by the somatic fusion of two different hybridoma cell lines; chemical conjugation based on chemical crosslinkers; and genetic methods using recombinant DNA technology.

BsAb Purification

As a professional antibody manufacture supplier in the world, Creative Biolabs has established a series of affinity purification methods, including Protein A chromatography, to handle expectations for more mature antibody production. Creative Biolabs has the aim to help clients to obtain high-quality BsAbs with higher purity, lower costs, and less time through multiple effective platforms.

BsAb Design

At the early stage of BsAb development, Creative Biolabs offers customized BsAb design services either for scientific research or clinical practice. More than that, Creative Biolabs can provide a full range of BsAbs to meet every customer's requirement.

Two BsAbs, Blinatumomab and Emicizumab, have been approved in the US and the EU, while a third BsAb, Catumaxomab, is already commercially available in the EU. 

Blinatumomab is a biopharmaceutical drug used as a second-line treatment for non-Hodgkin’s lymphoma or refractory acute lymphoblastic leukemia. It is a Bispecific T-Cell Engager (BiTE®), a small fusion protein containing two antibody binding sites.  One site binds to CD19 on cancer cells (e.g. Raji cells) and the other binds simultaneously to CD3 on T cells, thus linking the T lymphocytes to cancer cells expressing specific cancer antigens (e.g. CD19). The binding event potentiates unstimulated T cells and induces direct cytotoxicity against CD19+ cancer cells. 

 BPS has produced a CD19/CD3 BiTE® that is functionally identical to Blinatumomab. The ability of CD19/CD3 BiTE® to bind and activate T cells has been validated using several reporter cell lines.

 BPS Bioscience offers more bispecific antibodies, click here to consult the catalog.

Modified antibodies

Antibodies can be modified in many ways to create specific binding properties for different applications and therapeutic purposes.

Four categories of modified antibodies can be distinguished:

Recombinant 

Therapeutic 

Bispecific 

Labelled 

Explore the Biorbyt catalog of bispecific antibodies:

Substance P / HRP bispecific monoclonal antibody (P4C1)

Anti-BCMA bispecific antibody (DM16)

Anti-BCMA bispecific antibody (DM4)

Substance P / HRP Bispecific Monoclonal Antibody (P4C1)

GenScript ProBio SMABody(Single-domain antibody fused to monoclonal Ab) platform naturally combines the single domain antibody and the monoclonal antibody to make a bispecific antibody in symmetric format with good biological efficacy and good developability.

Purchase all these products through DBA Italia